Sponsoring the Targeted Cancer Therapy World Congress 2010 is a time and cost-effective opportunity to develop existing and new business.
Sponsorship packages offer your company thought-leadership positioning, branding, and the opportunity to set up face-to-face meetings with hundreds of decision makers from your target market in just 3 working days.
Chief Scientific Officer and Executive Vice President
Fresenius Biotech GmbH
Since 2008 Diane Seimetz, PhD, MDRA, is Executive Vice President and Chief Scientific Officer of Fresenius Biotech. In this function she is responsible for Clinical Development and Medical Affairs, Preclinical Development, Regulatory Affairs and Program Management. Diane Seimetz joined the Fresenius Healthcare Group in 1999 and has since then been closely involved in the development of the trifunctional antibody catumaxomab. This antibody is approved in the EU for the treatment of malignant ascites since April 2009. Diane Seimetz received her degree in pharmaceutical science in 1996 and completed her PhD at the University of Heidelberg in 1999. Her research work was conducted at the German Cancer Research Center and the Johns Hopkins University, where she worked towards glycotargeting in oncology. Diane Seimetz received her Master’s Degree in Drug Regulatory Affairs (MDRA) in 2002.
Appearing:
DAY 1 TUESDAY 21 SEPTEMBER – REGULATION & REIMBURSEMENT IN EUROPE
11.40am
Case study: the approval of Removab as EpCAM-targeted cancer therapy
Defining an indication by the expression of the target antigen – implications and things to consider from a regulatory perspective.
Understanding the step-by-step procedure to the approval of Removab as EpCAM targeted cancer therapy.
Continuing beyond approval – life cycle management and indication optimisation.
Dr Diane Seimetz,
Chief Scientific Officer and Executive Vice President, Fresenius Biotech GmbH
Sponsoring Targeted Cancer
Therapy World Congress 2010
is a time and cost-effective opportunity to develop
existing and new business.
Sponsorship packages offer your company thought-leadership positioning, branding, and the opportunity to set up face-to-face meetings with hundreds of decision makers from your target market in just 3 working days.
